Our Investments

Investment Activities

Breslin focuses on seed to early-stage investments as well as academic and industrial spin-offs, identifying and supporting high-potential ventures that drive technological innovation and market transformation. Leveraging deep industry expertise and a strong investment track record, we provide not only capital but also strategic guidance to help emerging companies navigate critical growth stages. By fostering innovation and connecting entrepreneurs with key stakeholders, we ensure that our investments generate long-term value and sustainable success.

Exited Portfolio Companies

Current Portfolio

Memo Therpeutics GmbH

A follow-on financing of $14 Million and spin-off from ETH, Zurich in 2015. Breslin forming founding partners and shareholders.

Qithera GmbH

Financing and development of a German cancer start-up. The start-up financing was successfully closed in 2020. With Breslin Shareholding.

CoBaLT GmbH

Financing and development of a German Medtech start-up. Currently, start-up financing is ongoing.

Exited Portfolio Companies

Actelion

Spin-Off of Actelion and introduction to Roche.

Participation in First Round Investment after Successful IPO in 2000.

Return to Dresdner Bank of $53 Million after
Investment of $3 Million.

Anawa

Founding, management and successful sale of one of the first Biotechs in Switzerland. Breslin majority holding.

GPC Biotech

Introduction of German Biotech Startups GPC and 4SC to Dresdner Allianz Bank.

Board Membership of Managing Partner of both GPC and 4SC. Both had strong exit performances.

Dresdner - Allianz

Sourcing, Introduction, Due Diligence, Financing and Managing – Biotech Company Interests for Allianz Dresdner.